Table 3 Key information of the SURMOUNT-1 trial [30]
From: CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
| Â | Tirzepatide, 5Â mg | Tirzepatide, 10Â mg | Tirzepatide, 15Â mg | Placebo |
|---|---|---|---|---|
least-squares mean (95% CI) | ||||
Co-primary endpointsa | ||||
Change in body weight (in %) | − 15.0 | − 19.5 | − 20.9 | − 3.1 |
Difference from placebo in percentage change in body weight (in %) | − 11.9 | − 16.4 | − 17.8 | – |
Weight reduction of 5% or more at week 72 (% of participants) | 85.1 | 88.9 | 90.9 | 34.5 |
Key secondary endpointsa | ||||
Weight reduction of 10% or more at week 72 (% of participants) | 68.5 | 78.1 | 83.5 | 18.8 |
Weight reduction of 15% or more at week 72 (% of participants) | 48.0 | 66.6 | 70.6 | 8.8 |
Weight reduction of 20% or more at week 72 (% of participants) | 30.0 | 50.1 | 56.7 | 3.1 |
Change in waist circumference (in cm) | − 14.0 | − 17.7 | − 18.5 | − 4.0 |
Difference from placebo in change in waist circumference (in cm) | − 10.1 | − 13.8 | − 14.5 | – |
Gastrointestinal (GI)-related adverse events (occurring in at least 5% of the participants) | ||||
Nausea (Event rate in %) | 24.6 | 33.3 | 31.0 | 9.5 |
Diarrhea (Event rate in %) | 18.7 | 21.2 | 23.0 | 7.3 |
Constipation (Event rate in %) | 16.8 | 17.1 | 11.7 | 5.8 |
Dyspepsia (Event rate in %) | 8.9 | 9.7 | 11.3 | 4.2 |
Vomiting (Event rate in %) | 8.3 | 10.7 | 12.2 | 1.7 |